Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinomaAly‐Khan A. Lalani, Toni K. Choueiri, Wanling Xie et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 267
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Noopur Raje, Siddhartha Mukherjee et al.|Proceedings of the National Academy of Sciences|2010Cited by 235
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinomaZiad Bakouny, Srinivas R. Viswanathan, Miriam Sant’Angelo et al.|Nature Communications|2021Cited by 167
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Dominick Bossé et al.|Cancer Immunology Research|2018Cited by 136
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R. McKay, Toni K. Choueiri, Bradley A. McGregor et al.|Journal of Clinical Oncology|2020Cited by 105